Literature DB >> 8205697

Blockade of platelet membrane glycoprotein Ib receptors delays intracoronary thrombogenesis, enhances thrombolysis, and delays coronary artery reocclusion in dogs.

S K Yao1, J C Ober, L I Garfinkel, Y Hagay, N Ezov, J J Ferguson, H V Anderson, A Panet, M Gorecki, L M Buja.   

Abstract

Von Willebrand factor and platelet membrane glycoprotein Ib receptors interact to mediate platelet adhesion and thrombogenesis in stenosed and endothelium-injured arteries. We wished to determine whether blocking glycoprotein Ib receptors with a recombinant von Willibrand factor binding domain (VCL) increases the time required for thrombus formation after injury to the coronary arteries. We also wished to determine whether, after thrombolysis with tissue plasminogen activator (TPA), VCL delays or protects against coronary artery reocclusion. Twenty-seven dogs were treated with either saline, VCL, or aspirin before thrombosis was induced in their coronary arteries by electrical injury. The time from injury to the formation of occlusive thrombi was significantly greater with VCL (70 +/- 10 minutes) and aspirin (69 +/- 20 minutes) than with saline (18 +/- 3 minutes, P < .001 and P < .05). Thrombosis was induced in 30 other dogs that then received thrombolytic treatment in four groups. Our major finding was that coronary artery reocclusion occurred in 72 +/- 11 minutes after treatment with TPA (80 micrograms/kg + 8 micrograms.kg-1.min-1) and heparin (200 U/kg) (n = 7); in 142 +/- 24 minutes after TPA, heparin, and VCL (4 mg/kg + 2 mg.kg-1.h-1) (n = 7) (compared with TPA and heparin, P < .05); in 74 +/- 13 minutes after TPA, heparin, and aspirin (5 mg/kg) (n = 8); and in 173 +/- 8 minutes after TPA, heparin, VCL, and aspirin (n = 8) (compared with TPA and heparin, P < .001). Thus, VCL increases the length of time required for thrombus formation in coronary arteries, and, when given with TPA and heparin, delays coronary artery reocclusion more effectively than aspirin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8205697     DOI: 10.1161/01.cir.89.6.2822

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

Review 1.  von Willebrand factor.

Authors:  Z M Ruggeri
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 2.  Future directions in thrombolysis.

Authors:  J T Willerson; P Zoldhelyi
Journal:  Clin Cardiol       Date:  1999-08       Impact factor: 2.882

3.  Humanized GPIbα-von Willebrand factor interaction in the mouse.

Authors:  Sachiko Kanaji; Jennifer N Orje; Taisuke Kanaji; Yuichi Kamikubo; Yosuke Morodomi; Yunfeng Chen; Alessandro Zarpellon; Jerome Eberhardt; Stefano Forli; Scot A Fahs; Rashmi Sood; Sandra L Haberichter; Robert R Montgomery; Zaverio M Ruggeri
Journal:  Blood Adv       Date:  2018-10-09

4.  A comparative study of the antithrombotic effect of aurintricarboxylic acid on arterial thrombosis in rats and guinea pigs.

Authors:  Y Takiguchi; M Shimazawa; M Nakashima
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

Review 5.  Novel antiplatelet agents: ALX-0081, a Nanobody directed towards von Willebrand factor.

Authors:  Jozef Bartunek; Emanuele Barbato; Guy Heyndrickx; Marc Vanderheyden; William Wijns; Josefin-Beate Holz
Journal:  J Cardiovasc Transl Res       Date:  2013-01-11       Impact factor: 4.132

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.